Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).

被引：0
|
作者：
Park, Keunchil
Lee, Jong-Seok
Lee, Ki Hyeong
Kim, Joo-Hang
Min, Young Joo
Cho, Jae Yong
Han, Ji-Youn
Kim, Bong-Seog
Kim, Jin-Soo
Lee, Dae Ho
Kang, Jin Hyoung
Cho, Eun Kyung
Jang, In-Jin
Jung, Jina
Kim, Hyo-Yeon
Sin, Hui Jung
Son, Jeewoong
Woo, Jong Soo
Kim, Dong-Wan
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol & Oncol, Seoul, South Korea
[2] Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul Natl Unvers,Bundang Hosp, Soengnam, South Korea
[3] Chungbuk Natl Univ Hosp, Cheongju, South Korea
[4] Yonsei Canc Ctr, Seoul, South Korea
[5] Ulsan Univ Hosp, Dept Med, Ulsan, South Korea
[6] Gangnam Severance Hosp, Seoul, South Korea
[7] Natl Canc Ctr, Goyang, South Korea
[8] VHS Med Ctr, Seoul, South Korea
[9] Seoul Natl Univ, Dept Internal Med, Boramae Med Ctr, Seoul, South Korea
[10] Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea
[11] Seoul St Marys Hosp, Seoul, South Korea
[12] Gachon Univ, Gil Med Ctr, Dept Internal Med, Div Hematol & Oncol, Inchon, South Korea
[13] Seoul Natl Univ Hosp, Dept Clin Pharmacol, Seoul 110744, South Korea
[14] Hanmi Pharmaceut Co Ltd, Seoul, South Korea
[15] Seoul Natl Univ Hosp, Seoul 110744, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8084
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PHASE I STUDY OF HM61713, A NOVEL EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT SELECTIVE INHIBITOR, IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS HAVING AN ACTIVATING EGFR MUTATION BUT FAILED TO PRIOR EGFR TYROSINE KINASE INHIBITOR (TKI) THERAPY
    Kim, Dong-Wan
    Kim, Sang-We
    Kim, Tae Min
    Lee, Se-Hoon
    Choi, Chang-Min
    Keam, Bhumsuk
    Lee, Jae Cheol
    Heo, Dae-Seog
    Lee, Jungshin
    Yu, Kyung-Sang
    Jang, In-Jin
    Lim, Kyung Joon
    Son, Jee-Woong
    Lee, Dae Ho
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S892 - S893
  • [2] Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs)
    Kim, Dong-Wan
    Lee, Dae Ho
    Kang, Jin Hyoung
    Park, Keunchil
    Han, Ji-Youn
    Lee, Jong-Seok
    Jang, In-Jin
    Kim, Hyo-Yeon
    Son, Jeewoong
    Kim, Joo-Hang
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] EGFR-TYROSINE KINASE INHIBITOR (TKI) RECHALLENGE WITH BEVACIZUMAB IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Otsuka, K.
    Hata, A.
    Kato, R.
    Takeshita, J.
    Okuda, C.
    Kaji, R.
    Masago, K.
    Fujita, S.
    Katakami, N.
    ANNALS OF ONCOLOGY, 2014, 25
  • [4] ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)
    Park, K.
    Han, J. -Y.
    Kim, D. -W.
    Bazhenova, L. A.
    Ou, S. -H.
    Pang, Y. -K.
    Hin, H. S.
    Juan, O.
    Song, J.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S139 - S139
  • [5] Efficacy and safety of epidermal growth factor receptor (EGFR) - Tyrosine kinase inhibitors (TKI) in elderly patients with EGFR mutation-positive non-small cell lung cancer (NSCLC)
    Takeyasu, Y.
    Goto, Y.
    Morita, R.
    Sato, J.
    Murakami, S.
    Horinouchi, H.
    Fujiwara, Y.
    Kanda, S.
    Yamamoto, N.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] ELUXA 1: Ph II study of BI1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)
    Ou, Sal -Hong
    Park, Keunchil
    Han, Ji-Youn
    Kim, Dong-Wan
    Bazhenova, Lyudmila
    Pang, Yong-Kek
    Hin, How Soon
    Juan, Oscar
    Son, Jeewoong
    Voccia, Isabelle
    Massey, Daniel
    Kim, Miyoung
    Janne, Pasi A.
    CANCER RESEARCH, 2016, 76
  • [7] Associations of C-MET Gene Copy with EGFR Mutation and Gene Copy in EGFR-Tyrosine Kinase Inhibitor (TKI) Untreated Non-Small Cell Lung Cancer (NSCLC)
    Bae, J. M.
    Jeon, Y. K.
    Kim, Y. T.
    Seo, J. W.
    Kim, Y. A.
    Chung, D. H.
    LABORATORY INVESTIGATION, 2010, 90 : 397A - 397A
  • [8] Associations of C-MET Gene Copy with EGFR Mutation and Gene Copy in EGFR-Tyrosine Kinase Inhibitor (TKI) Untreated Non-Small Cell Lung Cancer (NSCLC)
    Bae, J. M.
    Jeon, Y. K.
    Kim, Y. T.
    Seo, J. W.
    Kim, Y. A.
    Chung, D. H.
    MODERN PATHOLOGY, 2010, 23 : 397A - 397A
  • [9] EGFR Tyrosine Kinase Inhibitor and Chemotherapy in EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Nishino, Kazumi
    Kimura, Madoka
    Inoue, Takako
    Uchida, Junji
    Kumagai, Toru
    Imamura, Fumio
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S526 - S526
  • [10] A single-arm phase II study of afatinib treatment for advanced EGFR-mutant non-small cell lung cancer (mNSCLC) patients (pts) with EGFR-tyrosine kinase inhibitor (TKI) resistance.
    Bar, Jair
    Botser, Dana
    Navon, Rossie
    Peled, Nir
    Biran, Haim
    Gal-Yam, Einav Nili
    Ben-Arieh, Sayeh
    Raskin, Stephen
    Onn, Amir
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345